Latest News and Press Releases

Nutrition Segment increased Adjusted EBITDA* to $4M, representing 27% year-over-year and 17% sequential growth VAYA Pharma sales to patients grew 45% year-over-year, but inventory destocking by...

MIGDAL HA'EMEQ, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based...

MIGDAL HA'EMEQ, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid...

MIGDAL HA'EMEQ, Israel, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid...

VAYA Pharma Generated Record Net Revenues of $3.4 Million GAAP Diluted EPS Impacted by Decline in the Krill Oil Revenues Two U.S. Based Multinationals and...

MIGDAL HA'EMEQ, Israel, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and...

MIGDAL HA'EMEQ, Israel, July 26, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and...

In the news release, Enzymotec Ltd. Calls its 2016 Annual General Meeting of Shareholders, issued July 13, 2016 by Enzymotec Ltd., we are advised by the company of the following amendments to the...

MIGDAL HA’EMEQ, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (the “Company”), today announced that it will hold its 2016 Annual General Meeting of Shareholders (the...

Reports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash Flow  VAYA Pharma Generates Record Net Revenues of $3.1 Million ...